High density lipoprotein classification

Revision as of 21:03, 24 September 2013 by Gerald Chi (talk | contribs) (→‎Density)
Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

High density lipoprotein classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of High density lipoprotein classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on High density lipoprotein classification

CDC on High density lipoprotein classification

High density lipoprotein classification in the news

Blogs on High density lipoprotein classification

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for High density lipoprotein classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Hihg-density lipoprotein (HDL) is heterogeneous and dynamically switch between conformations. It does not represent one structure but a series of lipoproteins that are sequentially produced. Fractionated HDL particles vary in physiochemical property, cholesterol component, apolipoprotein composition, electrophoretic mobility, density, and biological function.[1][2]

Classification

High-density lipoproteins (HDLs) are highly heterogenous in their physiochemical characteristics due to the differences in relative composition of intercalated apolipoproteins thus may be separated based upon buoyant density, size, charge, or apolipoprotein composition. Moreover, the amphiphatic helical structure of apoA-I possesses a hinge domain that allows it to switch between different conformations corresponding to HDLs of variable size.[3] With density gradient ultracentrifugation, HDLs can be separated into HDL2, HDL3, and very-high-density lipoprotein (VHDL). Nondenaturing polyacrylamide gradient gel electrophoresis may also be used to fractionate HDLs into five distinct populations of descending size: HDL2b, HDL2a, HDL3a, HDL3b, and HDL3c.[4][5] Isopycnic density gradient ultracentrifugation has been used to analyze the fasting plasma to yield equivalent delineations as well.[6][7] Yet another method of classifying HDL lipoprotein particles by size is nuclear magnetic resonance (NMR).[8] Two-dimensional gel electrophoresis technique can be used to resolve HDL particles in the plasma into lipid-poor pre-β-HDLs and α-HDL that predominantly contains mature spherical cholesteryl esters.[9]

Density

HDLs may be ultracentrifugally fractionated into two major populations.[10][11][12]

Type Size Density
HDL2 1.063-1.125 g/ml 8.8 to 13 nm
HDL3 1.125-1.21 g/ml 7.3 to 8.2 nm

Size

HDL may be isolated on the basis of size by non-denaturing polyacrylamide gradient gel electrophoresis or by isopycnic density gradient ultracentrifugation.[10]

In order of decreasing size:[12]

  • HDL2b
  • HDL2a
  • HDL3a
  • HDL3b
  • HDL3c

Another classification is:

  • Very large HDL particles (VL-HDL)
  • Large HDL particles (L-HDL)
  • Medium HDL particles (M-HDL)
  • Small HDL particles (S-HDL)
  • Very-small HDL particles (VS-HDL)
  • Pre-β-1 HDL (role in macrophage cholesterol efflux)[1]

Apolipoprotein Content

High density lipoproteins can be immunoseparated on the basis of apolipoprotein composition into particles containing different apolipoproteins. The two major apolipoproteins found within HDL particles are the apoA-I and apoA-II.[13][14] Several other minor apolipoproteins associated with HDL include apoA-IV, apoA-V, apoC-I, apoC-II, apoC-III, and apoE.[15] However, LpA-I and LpA-I:LpA-II constitute the major portions of ciculating HDLs.

  • LpA-I (contains only apoA-I)
  • LpA-I:LpA-II (contains both apoA-I and apoA-II)
  • LpA-IV
  • LpE[10][12]

Surface Charge

HDL has been separated according to charge by agarose gel electrophoresis.[10]

Note that pre-beta < pre-alpha < alpha.

  • Pre-beta (positive)
  • Pre-alpha
  • Alpha (negative)

References

  1. 1.0 1.1 Rosenson RS, Brewer HB, Chapman MJ, Fazio S, Hussain MM, Kontush A; et al. (2011). "HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events". Clin Chem. 57 (3): 392–410. doi:10.1373/clinchem.2010.155333. PMID 21266551.
  2. Rosenson RS, Brewer HB, Ansell B, Barter P, Chapman MJ, Heinecke JW; et al. (2013). "Translation of High-Density Lipoprotein Function Into Clinical Practice: Current Prospects and Future Challenges". Circulation. 128 (11): 1256–1267. doi:10.1161/CIRCULATIONAHA.113.000962. PMID 24019446.
  3. Reschly, EJ.; Sorci-Thomas, MG.; Davidson, WS.; Meredith, SC.; Reardon, CA.; Getz, GS. (2002). "Apolipoprotein A-I alpha -helices 7 and 8 modulate high density lipoprotein subclass distribution". J Biol Chem. 277 (12): 9645–54. doi:10.1074/jbc.M107883200. PMID 11744719. Unknown parameter |month= ignored (help)
  4. Blanche, PJ.; Gong, EL.; Forte, TM.; Nichols, AV. (1981). "Characterization of human high-density lipoproteins by gradient gel electrophoresis". Biochim Biophys Acta. 665 (3): 408–19. PMID 7295744. Unknown parameter |month= ignored (help)
  5. Anderson, DW.; Nichols, AV.; Forte, TM.; Lindgren, FT. (1977). "Particle distribution of human serum high density lipoproteins". Biochim Biophys Acta. 493 (1): 55–68. PMID 195628. Unknown parameter |month= ignored (help)
  6. Goulinet, S.; Chapman, MJ. (1997). "Plasma LDL and HDL subspecies are heterogenous in particle content of tocopherols and oxygenated and hydrocarbon carotenoids. Relevance to oxidative resistance and atherogenesis". Arterioscler Thromb Vasc Biol. 17 (4): 786–96. PMID 9108795. Unknown parameter |month= ignored (help)
  7. Tall, AR.; Blum, CB.; Forester, GP.; Nelson, CA. (1982). "Changes in the distribution and composition of plasma high density lipoproteins after ingestion of fat". J Biol Chem. 257 (1): 198–207. PMID 6796585. Unknown parameter |month= ignored (help)
  8. Rifai, Nader.; Warnick, G. Russell.; Dominiczak, Marek H. (2000). Handbook of lipoprotein testin. Washington, DC: AACC Press. ISBN 1-890883-35-2.
  9. Asztalos, BF.; Schaefer, EJ. (2003). "High-density lipoprotein subpopulations in pathologic conditions". Am J Cardiol. 91 (7A): 12E–17E. PMID 12679198. Unknown parameter |month= ignored (help)
  10. 10.0 10.1 10.2 10.3 Krimbou L, Tremblay M, Davignon J, Cohn JS (1997). "Characterization of human plasma apolipoprotein E-containing lipoproteins in the high density lipoprotein size range: focus on pre-beta1-LpE, pre-beta2-LpE, and alpha-LpE". J Lipid Res. 38 (1): 35–48. PMID 9034198.
  11. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM (1981). "A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum". J Lipid Res. 22 (2): 339–58. PMID 6787159.
  12. 12.0 12.1 12.2 Rye KA, Barter PJ (2012). "Predictive value of different HDL particles for the protection against or risk of coronary heart disease". Biochim Biophys Acta. 1821 (3): 473–80. doi:10.1016/j.bbalip.2011.10.012. PMID 22051746.
  13. Brewer, HB.; Lux, SE.; Ronan, R.; John, KM. (1972). "Amino acid sequence of human apoLp-Gln-II (apoA-II), an apolipoprotein isolated from the high-density lipoprotein complex". Proc Natl Acad Sci U S A. 69 (5): 1304–8. PMID 4338591. Unknown parameter |month= ignored (help)
  14. Brewer, HB.; Fairwell, T.; LaRue, A.; Ronan, R.; Houser, A.; Bronzert, TJ. (1978). "The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins". Biochem Biophys Res Commun. 80 (3): 623–30. PMID 204308. Unknown parameter |month= ignored (help)
  15. Alaupovic, P. (1996). "Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins". Methods Enzymol. 263: 32–60. PMID 8748999.


Template:WikiDoc Sources